Does the ATG16L1 rs2241880 (T300A) variant increase risk of chronic intestinal inflammation?

The ATG16L1 rs2241880 (T300A) variant is a well-established genetic risk factor for chronic intestinal inflammation, specifically Crohn’s disease. This variant represents a critical intersection between genetic susceptibility, impaired cellular quality control, and dysregulated host-microbe interactions.

Clinical and effectiveness evidence

Large-scale genomic studies and meta-analyses consistently identify the rs2241880 (T300A) polymorphism as one of the most significant risk loci for Crohn’s disease (CD).

• Disease Specificity: The association is most robust for CD, particularly cases involving the ileum, with odds ratios typically ranging from 1.3 to 1.5 per risk allele (p < 10⁻¹⁰ in multiple GWAS). The association with ulcerative colitis (UC) is notably weaker or absent, highlighting its specific role in transmural inflammation.
• Population Impact: Evidence from cohorts exceeding 18,000 cases and 30,000 controls confirms that this threonine-to-alanine substitution at position 300 is a primary driver of disease susceptibility in European and North American populations.

Mechanistic explanations

The T300A variant alters the ATG16L1 protein in a way that makes it vulnerable to degradation during periods of cellular stress, such as infection or exposure to inflammatory cytokines like TNF-α.

• Caspase-Mediated Cleavage: The T300A substitution creates a hypersensitive cleavage site for caspase-3. When the cell is stressed, caspase-3 cleaves the ATG16L1 protein, leading to a loss of the functional WD40 domain required for "selective" autophagy.
• Impaired Xenophagy: This degradation specifically impairs xenophagy—the targeted autophagy of intracellular bacteria. Cells with the T300A variant fail to properly recruit LC3 to bacterial vacuoles, allowing pathogens like Salmonella and Adherent-Invasive E. coli (AIEC) to survive and replicate within the cytoplasm.
• Secondary Effects: Beyond bacterial clearance, the variant disrupts Paneth cell function. These specialized cells in the gut normally secrete antimicrobial peptides; in T300A carriers, Paneth cells exhibit secretory defects and increased endoplasmic reticulum (ER) stress, further destabilizing the intestinal barrier.

Clinical implications

The biological failure to manage intracellular bacteria triggers a compensatory, yet maladaptive, immune response.

• Inflammatory Signaling: The persistence of intracellular pathogens leads to chronic activation of pattern recognition receptors (PRRs) and elevated secretion of pro-inflammatory cytokines, specifically IL-1β and TNF-α.
• Pathophysiology: This cycle of impaired microbial handling, Paneth cell dysfunction, and chronic cytokine production drives the characteristic transmural inflammation and mucosal damage seen in chronic intestinal disease.

Bottom line

The ATG16L1 T300A variant is a major genetic susceptibility factor for Crohn’s disease. It acts by making the ATG16L1 protein susceptible to caspase-3 cleavage, which directly impairs the body's ability to clear intestinal bacteria via autophagy and leads to chronic, dysregulated inflammation.